Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Third-line Treatment”

235 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 235 results

Testing effectiveness (Phase 2)UnknownNCT05447715
What this trial is testing

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Weijian Guo 134
Not applicableLooking for participantsNCT06751953
What this trial is testing

Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment

Who this might be right for
Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University 10
Large-scale testing (Phase 3)Study completedNCT01271712
What this trial is testing

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

Who this might be right for
Gastrointestinal Stromal Tumors
Bayer 199
Testing effectiveness (Phase 2)Study completedNCT02945852
What this trial is testing

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Who this might be right for
Small Cell Lung Cancer
Fan Yun, MD 40
Not applicableActive Not RecruitingNCT05487248
What this trial is testing

On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

Who this might be right for
Unresectable Locally Advanced Colorectal CancerMetastatic Colorectal CancerCandidate for Third-line or Subsequent Lines of Therapy
Jules Bordet Institute 103
Not applicableUnknownNCT04768491
What this trial is testing

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Activating MutationNSCLC Stage IVNSCLC Stage IIIB+1 more
Peking Union Medical College 82
Large-scale testing (Phase 3)Study completedNCT00057720
What this trial is testing

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Telik 440
Large-scale testing (Phase 3)Study completedNCT02031744
What this trial is testing

The Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 530
Testing effectiveness (Phase 2)UnknownNCT05749133
What this trial is testing

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
XuYan 18
Testing effectiveness (Phase 2)UnknownNCT04179084
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Who this might be right for
Metastasis Colorectal Cancer
Chinese PLA General Hospital 30
Not applicableStudy completedNCT04161911
What this trial is testing

Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Who this might be right for
Hepatocellular Carcinoma
Bristol-Myers Squibb 1,426
Large-scale testing (Phase 3)Looking for participantsNCT06908304
What this trial is testing

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Who this might be right for
Carcinoma, Non-Small -Cell Lung
Maia Biotechnology 300
Testing effectiveness (Phase 2)UnknownNCT05894837
What this trial is testing

Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

Who this might be right for
Colorectal CancerLiver Metastases
Second Affiliated Hospital, School of Medicine, Zhejiang University 30
Testing effectiveness (Phase 2)Study completedNCT01003899
What this trial is testing

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 43
Testing effectiveness (Phase 2)WithdrawnNCT05315687
What this trial is testing

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Carcinoma in the Liver+1 more
Emory University
Testing effectiveness (Phase 2)Study completedNCT00889057
What this trial is testing

Sorafenib in Relapsed High Grade Osteosarcoma

Who this might be right for
Osteosarcoma
Italian Sarcoma Group 35
Testing effectiveness (Phase 2)Study completedNCT01124864
What this trial is testing

AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Who this might be right for
Non-small-cell Lung Cancer
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Study completedNCT05481463
What this trial is testing

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
Sun Yat-sen University 22
Not applicableLooking for participantsNCT06551207
What this trial is testing

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Who this might be right for
Metastatic Colorectal Cancer
Liu Huang 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04790474
What this trial is testing

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
Tel-Aviv Sourasky Medical Center 61
Load More Results